studied the long-term outcome (over 11 years) of loss-of-function variants in the TSHR gene and showed that SCH in heterozygous subjects is a stable compensated condition with an appropriately adjusted pituitary TSH set point and does not require replacement therapy (51). The gene discussed is TSHR; the disease is spindle cell hemangioma.